NCT00528294终止1 期
Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose.
研究概览
简要总结
This trials examines the feasibility of GRID-therapy combined with biologically imaging based IMRT (BG-IMRT). Within this trial, the strict toxicity parameters of primary treatment of head and neck tumors are used. The GRID and BG-IMRT technique might be possible to reduce the total radiation dose 2 to 3 times.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recurrent or new head or neck tumor
- •18 years or older
排除标准
- 未提供
结局指标
主要结局
Maximum tolerated dose.
时间窗: 3 months after end of treatment
Superior local control with Grid 18F-FDG-PET BG-IMRT using previously obtained maximum tolerated dose.
时间窗: 1 year.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck TumorHead and Neck TumorNCT00406289University Hospital, Ghent24
已完成
不适用
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor RanolazineAdenocarcinoma of the ProstateBone MetastasesSoft Tissue MetastasesStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT01992016University of Colorado, Denver11
已完成
不适用
18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic RadiosurgeryMetastatic Malignant NeoplasmMetastatic Malignant Neoplasm in the BoneNCT05174026M.D. Anderson Cancer Center10
已完成
1 期
A Phase I Study to Evaluate XTR003 in Healthy Chinese VolunteersCoronary Artery Disease (CAD)NCT05136391Sinotau Pharmaceutical Group10
撤回
不适用
Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot StudyCholangiocarcinomaNCT00604266University of Toronto